Regeneron Pharmaceuticals Inc (REGN)

Solvency ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Debt-to-assets ratio 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.09 0.11 0.12 0.12 0.00 0.00
Debt-to-capital ratio 0.06 0.06 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.09 0.09 0.10 0.10 0.12 0.14 0.15 0.16 0.00 0.00
Debt-to-equity ratio 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.09 0.09 0.10 0.10 0.11 0.11 0.13 0.17 0.18 0.20 0.00 0.00
Financial leverage ratio 1.29 1.28 1.28 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30

Regeneron Pharmaceuticals Inc's solvency ratios indicate a stable financial position over the analyzed period. The Debt-to-assets ratio has shown a gradual decline from 0.12 in September 2020 to 0.05 in December 2024, suggesting that the company has been effectively managing its debt in relation to its total assets.

Similarly, the Debt-to-capital ratio has followed a decreasing trend, signaling improved solvency as it decreased from 0.16 in September 2020 to 0.06 in December 2024. This indicates that the company's reliance on debt financing relative to its overall capital has decreased over time.

Moreover, the Debt-to-equity ratio also exhibited a declining pattern, falling from 0.20 in September 2020 to 0.07 by December 2024. This reduction suggests that the proportion of debt in the company's capital structure compared to equity has decreased, indicating a stronger financial position and lower financial risk.

The Financial leverage ratio, which indicates the company's reliance on debt financing, decreased from 1.30 in March 2020 to 1.29 in December 2024, showing a gradual reduction in financial leverage. This trend implies that the company has been prudent in managing its debt levels and has improved its overall financial stability.

Overall, the decreasing trends in these solvency ratios reflect Regeneron Pharmaceuticals Inc's ability to maintain a healthy balance between debt and assets, capital, and equity, indicating a strengthened solvency position and lower financial risk over the analyzed period.

Coverage ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Interest coverage 71.67 65.58 60.91 57.85 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22

The interest coverage ratio of Regeneron Pharmaceuticals Inc has shown varying trends over the periods analyzed. Generally, the interest coverage ratio measures a company's ability to meet its interest payments on outstanding debt.

From March 31, 2020, to December 31, 2021, the interest coverage ratio for Regeneron Pharmaceuticals Inc improved significantly, indicating the company's ability to comfortably cover its interest expenses with its earnings.

The ratio peaked at 163.75 on December 31, 2021, suggesting a strong financial position and robust earnings relative to its interest obligations. However, from March 31, 2022, to December 31, 2024, the interest coverage ratio gradually decreased, indicating a potential decrease in profitability or an increase in interest expenses relative to earnings.

It is essential for investors and stakeholders to monitor this ratio over time to assess the company's ability to service its debt obligations, manage financial risk, and sustain profitability. A declining trend in the interest coverage ratio may signal potential financial challenges for the company in meeting its interest payments going forward.

See also:

Regeneron Pharmaceuticals Inc Solvency Ratios (Quarterly Data)